TL;DR
This study identifies aprepitant, an antiemetic drug, as a potent sensitizer for azole antifungals against the dangerous pathogen Candida auris. The combination of aprepitant and itraconazole not only restores azole susceptibility but also exhibits fungicidal activity against biofilms and significantly improves survival in a C. elegans infection model, suggesting a promising new therapeutic strategy.
What Problem Does This Paper Address?
Candida auris is an emerging global health threat, notorious for its multidrug resistance, particularly to azole antifungals, which are the primary treatment for invasive candidiasis. This resistance, coupled with C. auris's ability to form biofilms and transmit easily, makes infections difficult to treat and often fatal. The urgent need for new strategies to combat these infections has driven research into combination therapies that can restore the efficacy of existing drugs or overcome resistance mechanisms. This paper investigates whether aprepitant, an antiemetic agent, can act as such a sensitizer for azole drugs against C. auris.
Methods
The researchers employed a multi-pronged approach:
- Microdilution Checkerboard Assays: This standard method was used to evaluate the synergistic, additive, or indifferent interactions between aprepitant and azole drugs (fluconazole, voriconazole, and itraconazole) against various Candida species. The Fractional Inhibitory Concentration Index (ΣFICI) was calculated to quantify these interactions.
- Time-Kill Assays: These assays were used to determine the killing kinetics of the aprepitant/itraconazole combination against planktonic C. auris cells over time.
- Biofilm Assays (XTT Reduction Assay): The efficacy of the combination against both premature and mature C. auris biofilms was assessed by measuring metabolic activity.
- Caenorhabditis elegans Infection Model: This in vivo model was used to evaluate the therapeutic efficacy of the aprepitant/itraconazole combination by measuring fungal burden and survival rates in infected nematodes.
- Transcriptomic Profiling (RNA-Seq): This technique was employed to identify global changes in gene expression in C. auris treated with aprepitant, itraconazole, or the combination, aiming to elucidate the underlying molecular mechanisms.
- Quantitative Reverse Transcription PCR (RT-qPCR): Used to validate the RNA-Seq findings for specific differentially expressed genes.
- Reactive Oxygen Species (ROS) Detection: Assays were conducted to measure intracellular ROS levels in C. auris cells treated with the drugs, investigating the impact on cellular defense mechanisms.
- Iron Supplementation Assays: Time-kill and spot assays were performed with iron supplementation to investigate the role of metal ion homeostasis in the observed synergistic effects.
Datasets
The study utilized clinical isolates of Candida auris obtained from the Antimicrobial Resistance Isolate Bank (CDC), as well as other medically important Candida species (C. albicans, C. glabrata, C. krusei, C. tropicalis, and C. parapsilosis) from various sources. The RNA-Seq data generated in this study was deposited in the NCBI Sequence Read Archive (GEO) under accession number GSE148749.
Key Insights and Ideas
- Drug Repurposing Success: Aprepitant, an antiemetic, unexpectedly emerged as a potent azole chemosensitizer, highlighting the potential of repurposing existing drugs for novel antimicrobial applications.
- Metal Ion Homeostasis as a Target: The synergistic effect of aprepitant/itraconazole appears to be significantly mediated by disrupting metal ion homeostasis, particularly iron transport, in C. auris. This is a novel mechanism for azole potentiation.
- ROS Imbalance as a Consequence: The disruption of metal ion homeostasis leads to compromised ROS detoxification, resulting in elevated intracellular ROS levels, which likely contributes to the fungicidal activity of the combination.
- Broad-Spectrum Efficacy: The synergistic interaction isn't limited to C. auris; it extends to other clinically relevant Candida species, suggesting a broad therapeutic potential.
- Biofilm Disruption: The combination effectively targets both the formation and established presence of C. auris biofilms, a critical virulence factor that often renders antifungal treatments ineffective.
Key Results
- Aprepitant reduced the minimum inhibitory concentration (MIC) of itraconazole against C. auris by up to eight-fold.
- The aprepitant/itraconazole combination inhibited C. auris biofilm formation by 95% and disrupted mature biofilms by 52%.
- In a C. elegans model, the combination reduced fungal burden by 92% and increased nematode survival by 90% over five days.
- Synergistic interactions (ΣFICI as low as 0.08) were observed with itraconazole against multiple Candida species, including C. albicans, C. krusei, C. tropicalis, and C. parapsilosis.
- Transcriptomic analysis revealed significant downregulation of genes involved in metal ion transport (e.g., FTR1, ZRT2, CTR1) and upregulation of ergosterol biosynthesis genes (e.g., ERG1, ERG2, ERG10) in the presence of the combination.
- The combination significantly increased intracellular ROS levels in C. auris by approximately 600% compared to untreated controls.
- Iron supplementation reversed the fungicidal effect of the aprepitant/itraconazole combination, confirming the critical role of iron homeostasis.
Limitations and Future Work
The authors acknowledge that while iron supplementation significantly impacted the synergistic interaction, copper supplementation did not. They also noted an immediate precipitation reaction when zinc sulfate was mixed with aprepitant, preventing the investigation of zinc's role.
Future work should focus on:
- Further elucidating the precise molecular mechanisms by which aprepitant interferes with metal ion homeostasis and its downstream effects on ROS detoxification and ergosterol biosynthesis.
- Investigating the efficacy of this combination in higher animal models to assess its therapeutic potential more comprehensively.
- Conducting clinical studies to evaluate the safety and efficacy of aprepitant/itraconazole for treating invasive Candida infections, particularly those caused by multidrug-resistant strains.
Summary updated